A cell-permeable LXR inverse agonist that induces LXR-corepressor interaction at nanomolar concentrations; disrupts the Warburg effect in cancer cells in culture and in vivo, suppressing the expression of glycolytic and lipogenic genes and reducing glycolytic metabolites and lipid production.